The effect of Toxoplasma cell fractions and mycobacterial immunostimulants against virulent Toxoplasma gondii in mice.
Toxoplasma gondii tachyzoites were disrupted in a Ribi cell fractionator and separated into cell walls and protoplasm by differential centrifugation. These products were used alone or combined with a mycobacterial glycolipid (P3) and injected either as oil-in-water emulsions or incorporated in Freund's incomplete adjuvant. Mice were vaccinated by intravenous or intradermal routes and challenged intraperitoneally with a highly virulent strain of Toxoplasma gondii. A local granuloma formation was induced after i.d. inoculation of Toxoplasma vaccines containing P3 as this glycolipid enabled an adherence of the antigens on the mineral oil droplets. The adjuvant effect of P3 on antibody formation was also observed. Most of the fractions showed a low, but statistically significant prolongation of survival time. Vaccination by the i.v. route with homologous or heterologous antigens, including Trypanosoma cruzi, were not significantly effective, with the exception of a high dose of Toxoplasma protoplasm associated with P3.
D000276:Adjuvants, Immunologic / Q000276:immunology*; D000818:Animals; D000941:Antigens / Q000276:immunology*; D002473:Cell Wall / Q000276:immunology; D003593:Cytoplasm / Q000276:immunology; D005260:Female; D006017:Glycolipids / Q000276:immunology*; D051379:Mice; D009163:Mycobacterium bovis / Q000276:immunology*; D013347:Subcellular Fractions / Q000276:immunology; D014122:Toxoplasma / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000517:prevention & control*; D014349:Trypanosoma cruzi / Q000276:immunology; D014611:Vaccination
D000276:Adjuvants, Immunologic; D000941:Antigens; D006017:Glycolipids